Atlas Trials

Anti-angiOpoeitin 2 Plus Anti-vascular eNdothelial Growth Factor as a therapY for Neovascular Age Related Macular Degeneration: Evaluation of a fiXed Combination Intravitreal Injection

Clinical trial NCT02713204 · COMPLETED

Trial details

NCT number
NCT02713204
Sponsor
Regeneron Pharmaceuticals
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Neovascular Age-Related Macular Degeneration
Start date
2016-03-31
Primary completion
2017-10-03
Enrollment
365

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.